Stoboclo Purple Book BLA 761404

BLA number
761404
Proprietary names
Stoboclo, Osenvelt
Proper names
denosumab-bmwo
Applicant
CELLTRION, Inc.
Center
CDER
First observed release
2025-03-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Stoboclodenosumab-bmwo351(k) Interchangeable60MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2025-02-28
002Osenveltdenosumab-bmwo351(k) Interchangeable120MG/1.7ML (70MG/ML)InjectionSubcutaneousSingle-Dose VialRxLicensed2025-02-28

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125320Proliadenosumab351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-11-01U001Stoboclo351(k) InterchangeableRxCELLTRION, Inc.
2025-11-01U002Osenvelt351(k) InterchangeableRxCELLTRION, Inc.
2025-03-01N001Stoboclo351(k) BiosimilarRxCELLTRION, Inc.
2025-03-01N002Osenvelt351(k) BiosimilarRxCELLTRION, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-11-01001Stoboclo351(k) InterchangeableRxLicensed2025-02-28
2025-11-01002Osenvelt351(k) InterchangeableRxLicensed2025-02-28
2025-03-01001Stoboclo351(k) BiosimilarRxLicensed2025-02-28
2025-03-01002Osenvelt351(k) BiosimilarRxLicensed2025-02-28